| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2024 ( Subtotal = $243,950 ) |
| | 2024 | 2024 | UNIVERSITY OF BATH | CLAVERTON DOWN | BATH | | | | GBR | U01FD007957 | Development and Validation of a Multi-functional, Multi-purpose Quantitative Tool for Dermal Physiologically-Based Pharmacokinetic Modeling | 000 | 2 | FDA | 8/28/2024 | $243,950 |
| | 2024 | 2023 | UNIVERSITY OF BATH | CLAVERTON DOWN | BATH | | | | GBR | U01FD007660 | Development of PBBM Framework to Support an Assessment of Bioequivalence for Locally-Acting Drugs in the Gastrointestinal Tract in Healthy Subjects and Patients | 000 | 2 | FDA | 2/16/2024 | $0 |
| | 2024 | 2023 | UNIVERSITY OF BATH | CLAVERTON DOWN | BATH | | | | GBR | U01FD007660 | Development of PBBM Framework to Support an Assessment of Bioequivalence for Locally-Acting Drugs in the Gastrointestinal Tract in Healthy Subjects and Patients | 001 | 2 | FDA | 6/24/2024 | $0 |
| | 2024 | 2022 | UNIVERSITY OF BATH | CLAVERTON DOWN | BATH | | | | GBR | U01FD006533 | Assessing the skin pharmacokinetics of topical drugs, and the bio(in)equivalence of topical drug products, using non-invasive techniques | 000 | 5 | FDA | 6/13/2024 | $0 |
|
| Issue Date FY: 2023 ( Subtotal = $511,622 ) |
| | 2023 | 2023 | UNIVERSITY OF BATH | CLAVERTON DOWN | BATH | | | | GBR | U01FD007957 | Development and Validation of a Multi-functional, Multi-purpose Quantitative Tool for Dermal Physiologically-Based Pharmacokinetic Modeling | 001 | 1 | FDA | 9/23/2023 | $0 |
| | 2023 | 2023 | UNIVERSITY OF BATH | CLAVERTON DOWN | BATH | | | | GBR | U01FD007957 | Development and Validation of a Multi-functional, Multi-purpose Quantitative Tool for Dermal Physiologically-Based Pharmacokinetic Modeling | 003 | 1 | FDA | 9/28/2023 | $242,154 |
| | 2023 | 2023 | UNIVERSITY OF BATH | CLAVERTON DOWN | BATH | | | | GBR | U01FD007957 | Development and Validation of a Multi-functional, Multi-purpose Quantitative Tool for Dermal Physiologically-Based Pharmacokinetic Modeling | 000 | 1 | FDA | 9/12/2023 | $242,154 |
| | 2023 | 2023 | UNIVERSITY OF BATH | CLAVERTON DOWN | BATH | | | | GBR | U01FD007957 | Development and Validation of a Multi-functional, Multi-purpose Quantitative Tool for Dermal Physiologically-Based Pharmacokinetic Modeling | 002 | 1 | FDA | 9/27/2023 | -$242,154 |
| | 2023 | 2023 | UNIVERSITY OF BATH | CLAVERTON DOWN | BATH | | | | GBR | U01FD007660 | Development of PBBM Framework to Support an Assessment of Bioequivalence for Locally-Acting Drugs in the Gastrointestinal Tract in Healthy Subjects and Patients | 000 | 2 | FDA | 8/24/2023 | $295,152 |
| | 2023 | 2022 | UNIVERSITY OF BATH | CLAVERTON DOWN | BATH | | | | GBR | U01FD006533 | Assessing the skin pharmacokinetics of topical drugs, and the bio(in)equivalence of topical drug products, using non-invasive techniques | 000 | 5 | FDA | 12/2/2022 | $0 |
| | 2023 | 2022 | UNIVERSITY OF BATH | CLAVERTON DOWN | BATH | | | | GBR | U01FD006533 | Assessing the skin pharmacokinetics of topical drugs, and the bio(in)equivalence of topical drug products, using non-invasive techniques | 001 | 5 | FDA | 8/2/2023 | $0 |
| | 2023 | 2019 | UNIVERSITY OF BATH | CLAVERTON DOWN | BATH | | | | GBR | R01DA007315 | Discovery of New treatments for Drug Abuse | 000 | 25 | NIH | 1/17/2023 | -$25,684 |
|
| Issue Date FY: 2022 ( Subtotal = $537,813 ) |
| | 2022 | 2022 | UNIVERSITY OF BATH | CLAVERTON DOWN | BATH | | | | GBR | U01FD006533 | Assessing the skin pharmacokinetics of topical drugs, and the bio(in)equivalence of topical drug products, using non-invasive techniques | 001 | 5 | FDA | 8/19/2022 | $249,919 |
| | 2022 | 2022 | UNIVERSITY OF BATH | CLAVERTON DOWN | BATH | | | | GBR | U01FD007660 | Development of PBBM Framework to Support an Assessment of Bioequivalence for Locally-Acting Drugs in the Gastrointestinal Tract in Healthy Subjects and Patients | 000 | 1 | FDA | 9/8/2022 | $287,894 |
| | 2022 | 2021 | UNIVERSITY OF BATH | THE AVENUE | BATH | AVON | | | GBR | U01FD006533 | Assessing the skin pharmacokinetics of topical drugs, and the bio(in)equivalence of topical drug products, using non-invasive techniques | 000 | 4 | FDA | 11/15/2021 | $0 |
|
| Issue Date FY: 2021 ( Subtotal = $234,784 ) |
| | 2021 | 2021 | UNIVERSITY OF BATH | THE AVENUE | BATH | AVON | | | GBR | U01FD006533 | Assessing the skin pharmacokinetics of topical drugs, and the bio(in)equivalence of topical drug products, using non-invasive techniques | 001 | 4 | FDA | 8/13/2021 | $249,999 |
| | 2021 | 2020 | UNIVERSITY OF BATH | THE AVENUE | BATH | AVON | | | GBR | U01FD006533 | Assessing the skin pharmacokinetics of topical drugs, and the bio(in)equivalence of topical drug products, using non-invasive techniques | 000 | 3 | FDA | 11/4/2020 | $0 |
| | 2021 | 2019 | UNIVERSITY OF BATH | THE AVENUE | BATH | AVON | | | GBR | R01DA007315 | Discovery of New treatments for Drug Abuse | 000 | 25 | NIH | 12/1/2020 | $0 |
| | 2021 | 2014 | UNIVERSITY OF BATH | THE AVENUE | BATH | AVON | | | GBR | U01FD004953 | Development of an In Vitro Dissolution Technique to Understand the Clinical Based | 000 | 2 | FDA | 4/8/2021 | -$15,215 |
|
| Issue Date FY: 2020 ( Subtotal = $249,999 ) |
| | 2020 | 2020 | UNIVERSITY OF BATH | THE AVENUE | BATH | AVON | BA2 7AY | | GBR | U01FD006533 | Assessing the skin pharmacokinetics of topical drugs, and the bio(in)equivalence of topical drug products, using non-invasive techniques | 001 | 3 | FDA | 7/24/2020 | $249,999 |
| | 2020 | 2019 | UNIVERSITY OF BATH | THE AVENUE | BATH | AVON | BA2 7AY | | GBR | U01FD006533 | Assessing the skin pharmacokinetics of topical drugs, and the bio(in)equivalence of topical drug products, using non-invasive techniques | 000 | 2 | FDA | 12/13/2019 | $0 |
|
| Issue Date FY: 2019 ( Subtotal = $615,574 ) |
| | 2019 | 2019 | UNIVERSITY OF BATH | THE AVENUE | BATH | AVON | BA2 7AY | | GBR | R01DA007315 | Discovery of New treatments for Drug Abuse | 000 | 25 | NIH | 11/30/2018 | $365,574 |
| | 2019 | 2019 | UNIVERSITY OF BATH | THE AVENUE | BATH | AVON | BA2 7AY | | GBR | U01FD006533 | Assessing the skin pharmacokinetics of topical drugs, and the bio(in)equivalence of topical drug products, using non-invasive techniques | 001 | 2 | FDA | 8/6/2019 | $250,000 |
| | 2019 | 2018 | UNIVERSITY OF BATH | THE AVENUE | BATH | AVON | BA2 7AY | | GBR | U01FD006533 | Assessing the skin pharmacokinetics of topical drugs, and the bio(in)equivalence of topical drug products, using non-invasive techniques | 000 | 1 | FDA | 6/19/2019 | $0 |
|
| Issue Date FY: 2018 ( Subtotal = $615,574 ) |
| | 2018 | 2018 | UNIVERSITY OF BATH | THE AVENUE | BATH | AVON | BA2 7AY | | GBR | U01FD006533 | Assessing the skin pharmacokinetics of topical drugs, and the bio(in)equivalence of topical drug products, using non-invasive techniques | 001 | 1 | FDA | 8/29/2018 | $250,000 |
| | 2018 | 2018 | UNIVERSITY OF BATH | THE AVENUE | BATH | AVON | BA2 7AY | | GBR | R01DA007315 | Discovery of New treatments for Drug Abuse | 000 | 24 | NIH | 11/28/2017 | $329,016 |
| | 2018 | 2018 | UNIVERSITY OF BATH | THE AVENUE | BATH | AVON | BA2 7AY | | GBR | U01FD006533 | Assessing the skin pharmacokinetics of topical drugs, and the bio(in)equivalence of topical drug products, using non-invasive techniques | 002 | 1 | FDA | 9/14/2018 | $0 |
| | 2018 | 2018 | UNIVERSITY OF BATH | THE AVENUE | BATH | AVON | BA2 7AY | | GBR | R01DA007315 | Discovery of New treatments for Drug Abuse | 001 | 24 | NIH | 4/26/2018 | $36,558 |
| | 2018 | 2018 | UNIVERSITY OF BATH | THE AVENUE | BATH | AVON | BA2 7AY | | GBR | U01FD006533 | Assessing the skin pharmacokinetics of topical drugs, and the bio(in)equivalence of topical drug products, using non-invasive techniques | 000 | 1 | FDA | 8/27/2018 | $250,000 |
| | 2018 | 2018 | UNIVERSITY OF BATH | THE AVENUE | BATH | AVON | BA2 7AY | | GBR | U01FD006533 | Assessing the skin pharmacokinetics of topical drugs, and the bio(in)equivalence of topical drug products, using non-invasive techniques | 001 | 1 | FDA | 8/29/2018 | -$250,000 |
|
| Issue Date FY: 2017 ( Subtotal = $337,889 ) |
| | 2017 | 2017 | UNIVERSITY OF BATH | THE AVENUE | BATH | AVON | BA2 7AY | | GBR | R01DA007315 | Discovery of New treatments for Drug Abuse | 000 | 23 | NIH | 11/15/2016 | $329,016 |
| | 2017 | 2017 | UNIVERSITY OF BATH | THE AVENUE | BATH | AVON | BA2 7AY | | GBR | R01DA007315 | Discovery of New treatments for Drug Abuse | 001 | 23 | NIH | 5/22/2017 | $36,558 |
| | 2017 | 2011 | UNIVERSITY OF BATH | THE AVENUE | BATH | AVON | BA2 7AY | | GBR | U01FD004321 | Quality by Design of orally inhaled drug products: Chemistry, Manufacturing and C | 000 | 1 | FDA | 4/4/2017 | -$27,685 |
|
| Issue Date FY: 2016 ( Subtotal = $411,895 ) |
| | 2016 | 2016 | University of Bath | Claverton Down | Bath | | | | GBR | U01FD004953 | Development of an In Vitro Dissolution Technique to Understand the Clinical Based | 001 | 2 | FDA | 6/17/2016 | $49,977 |
| | 2016 | 2016 | University of Bath | Claverton Down | Bath | | | | GBR | R01DA007315 | Discovery of New treatments for Drug Abuse | 001 | 22 | NIH | 3/8/2016 | $32,902 |
| | 2016 | 2016 | University of Bath | Claverton Down | Bath | | | | GBR | R01DA007315 | Discovery of New treatments for Drug Abuse | 000 | 22 | NIH | 11/19/2015 | $329,016 |
| | 2016 | 2014 | University of Bath | Claverton Down | Bath | | | | GBR | U01FD004953 | Development of an In Vitro Dissolution Technique to Understand the Clinical Based | 000 | 2 | FDA | 6/17/2016 | $0 |
|
| Issue Date FY: 2015 ( Subtotal = $377,119 ) (Continued on the next page) |
| | 2015 | 2015 | University of Bath | Claverton Down | Bath | | | | GBR | R01DA007315 | Discovery of New treatments for Drug Abuse | 002 | 21 | NIH | 3/23/2015 | $365,870 |
| | 2015 | 2015 | University of Bath | Claverton Down | Bath | | | | GBR | R01DA007315 | Discovery of New treatments for Drug Abuse | 001 | 21 | NIH | 3/13/2015 | -$365,870 |
| | 2015 | 2015 | University of Bath | Claverton Down | Bath | | | | GBR | R01DA007315 | Discovery of New treatments for Drug Abuse | 000 | 21 | NIH | 1/30/2015 | $365,870 |
|
